ATE541573T1 - Pharmazeutische zusammensetzung enthaltend lapatinib - Google Patents
Pharmazeutische zusammensetzung enthaltend lapatinibInfo
- Publication number
- ATE541573T1 ATE541573T1 AT09782127T AT09782127T ATE541573T1 AT E541573 T1 ATE541573 T1 AT E541573T1 AT 09782127 T AT09782127 T AT 09782127T AT 09782127 T AT09782127 T AT 09782127T AT E541573 T1 ATE541573 T1 AT E541573T1
- Authority
- AT
- Austria
- Prior art keywords
- pharmaceutical composition
- composition containing
- lapatinib
- containing lapatinib
- composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0007—Effervescent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08014984A EP2158913A1 (de) | 2008-08-25 | 2008-08-25 | Pharmazeutische Zusammensetzung mit N-[3-chlor-4-(3-fluorophenyl)methoxy)phenyl)6-(5(((2-(methylsulfonyl)ethyl)amino)methyl)-2-furyl)-4-chinazolinamin |
PCT/EP2009/060890 WO2010023188A1 (en) | 2008-08-25 | 2009-08-24 | Pharmaceutical composition comprising n-[3-chloro-4-[(3- fluorophenyl)methoxy]phenyl]-6-[5[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4- quinazolinamine |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE541573T1 true ATE541573T1 (de) | 2012-02-15 |
Family
ID=39884161
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT09782127T ATE541573T1 (de) | 2008-08-25 | 2009-08-24 | Pharmazeutische zusammensetzung enthaltend lapatinib |
Country Status (7)
Country | Link |
---|---|
US (1) | US8586091B2 (de) |
EP (2) | EP2158913A1 (de) |
AT (1) | ATE541573T1 (de) |
CA (1) | CA2735206C (de) |
ES (1) | ES2378134T3 (de) |
RU (1) | RU2011107140A (de) |
WO (1) | WO2010023188A1 (de) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2958552B1 (de) | 2013-02-19 | 2017-06-21 | Hexal AG | Pharmazeutische zusammensetzung mit n-[3-chlor-4-(3-fluorbenzyloxy)phenyl]-6-[5({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]chinazolin-4-amin oder ein pharmazeutisch akzeptables salz, solvat oder solvatisiertes salz daraus |
WO2018137020A1 (en) | 2017-01-25 | 2018-08-02 | Pacey Medtech Ltd. | Distributed pressure fenestrated urethral compression apparatus for treatment of male urinary sphincter deficiency with preservation of blood flow |
EP3687500A1 (de) * | 2017-09-29 | 2020-08-05 | Crititech, Inc. | Glucocorticoidpartikel und deren verwendung |
TWI832871B (zh) | 2018-06-29 | 2024-02-21 | 美商英塞特公司 | Axl/mer 抑制劑之調配物 |
EP3846787A4 (de) * | 2018-09-03 | 2022-05-25 | BDR Pharmaceuticals International Private Limited | Neuartige zusammensetzung von lapatinib in oraler fester darreichungsform und verfahren zu ihrer herstellung |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8623557D0 (en) * | 1986-10-01 | 1986-11-05 | Boots Co Plc | Therapeutic agents |
RS49779B (sr) | 1998-01-12 | 2008-06-05 | Glaxo Group Limited, | Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze |
KR100815681B1 (ko) | 2000-06-30 | 2008-03-20 | 글락소 그룹 리미티드 | 퀴나졸린 디토실레이트 염 화합물 |
ES2233227T1 (es) * | 2003-03-26 | 2005-06-16 | Teva Pharmaceutical Industries Ltd. | Procedimiento para la preparacion de ingredientes farmaceuticos activos con un area superficial especifica. |
US20080026067A1 (en) | 2004-04-20 | 2008-01-31 | Kuwabe Shin-Itsu | Method for Increasing Specific Surface Area of Slightly Soluble Drug |
WO2005120504A2 (en) | 2004-06-03 | 2005-12-22 | Smithkline Beecham (Cork) Limited | Cancer treatment method |
EP2277595A3 (de) | 2004-06-24 | 2011-09-28 | Novartis Vaccines and Diagnostics, Inc. | Verbindungen zur Immunopotenzierung |
ES2426007T3 (es) | 2004-12-17 | 2013-10-18 | Smithkline Beecham (Cork) Limited | Método para el tratamiento del cáncer |
KR20080002939A (ko) | 2005-04-12 | 2008-01-04 | 엘란 파마 인터내셔널 리미티드 | 나노입자형 퀴나졸린 유도체 제제 |
KR101356748B1 (ko) | 2005-04-19 | 2014-02-06 | 스미스클라인 비이참 (코르크) 리미티드 | 약제 조성물 |
WO2007143483A2 (en) * | 2006-06-01 | 2007-12-13 | Smithkline Beecham Corporation | Combination of pazopanib and lapatinib for treating cancer |
EP2088862A4 (de) * | 2006-11-28 | 2009-12-02 | Smithkline Beecham Cork Ltd | Krebsbehandlungsverfahren |
EP2158912A1 (de) * | 2008-08-25 | 2010-03-03 | Ratiopharm GmbH | Pharmazeutische Zusammensetzung mit N-[3-chlor-4-(3-fluorophenyl)methoxy)phenyl)6-(5(((2-(methylsulfonyl)ethyl)amino)methyl)-2-furyl)-4-chinazolinamin |
CA2740977A1 (en) * | 2008-11-03 | 2010-06-03 | Natco Pharma Limited | A novel process for the preparation of lapatinib and its pharmaceutically acceptable salts |
-
2008
- 2008-08-25 EP EP08014984A patent/EP2158913A1/de not_active Withdrawn
-
2009
- 2009-08-24 WO PCT/EP2009/060890 patent/WO2010023188A1/en active Application Filing
- 2009-08-24 US US13/060,750 patent/US8586091B2/en not_active Expired - Fee Related
- 2009-08-24 RU RU2011107140/15A patent/RU2011107140A/ru not_active Application Discontinuation
- 2009-08-24 EP EP09782127A patent/EP2320902B1/de not_active Revoked
- 2009-08-24 AT AT09782127T patent/ATE541573T1/de active
- 2009-08-24 ES ES09782127T patent/ES2378134T3/es active Active
- 2009-08-24 CA CA2735206A patent/CA2735206C/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US20110305762A1 (en) | 2011-12-15 |
US8586091B2 (en) | 2013-11-19 |
CA2735206A1 (en) | 2010-03-04 |
RU2011107140A (ru) | 2012-09-27 |
WO2010023188A1 (en) | 2010-03-04 |
ES2378134T3 (es) | 2012-04-09 |
EP2320902A1 (de) | 2011-05-18 |
EP2158913A1 (de) | 2010-03-03 |
EP2320902B1 (de) | 2012-01-18 |
CA2735206C (en) | 2016-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2009000349A1 (es) | Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer. | |
JO2973B1 (en) | Fumarate salt for (alpha-beta-R) -6-bromo-alpha-[2- (methylamino) ethyl-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinoline ethanol | |
CY1119474T1 (el) | Κρυσταλλικες μορφες 5-χλωρο-ν2-(2-ισοπροποξυ-5-μεθυλ-4-πιπεριδιν-4-υλ-φαινυλ)-ν4[2-(προπανο-2-σουλφονυλ)-φαινυλ]-πυριμιδιν-2,4-διαμινης | |
EA201500430A1 (ru) | Соединения боронатного эфира и его фармацевтические составы | |
BRPI0923728A2 (pt) | "método de preparação de compostos de di-hidroindeno amida, suas composições farmacêuticas contendo esses compostos e uso como inibidor de proteína quinase". | |
CY1109010T1 (el) | γ-ΚΡΥΣΤΑΛΛΙΚΗ ΜΟΡΦΗ ΤΗΣ ΥΔΡΟΧΛΩΡΙΚΗΣ ΙΒΑΒΡΑΔΙΝΗΣ, ΜΕΘΟΔΟΣ ΠΑΡΑΣΚΕΥΗΣ ΤΗΣ ΚΑΙ ΦΑΡΜΑΚΕΥΤΙΚΕΣ ΣΥΝΘΕΣΕΙΣ ΠΟΥ ΤΗΝ ΠΕΡΙΕΧΟΥΝ | |
CY1109998T1 (el) | Ενδυναμωτες υποδοχεων γλουταμινικου | |
BRPI0906064A2 (pt) | "peptídeo, processo para obtenção de um peptídeo de fórmula geral (i), composição cosmética ou farmacêutica e uso de um peptídeo de fórmula geral (i)" | |
FR16C1025I1 (fr) | Sel de 4-[[4-[[4-(2-Cyanoethenyl)-2,6-dimethylphenyl]amino]-2-Pyrimidinyl]amino]benzonitrile | |
EA200970500A1 (ru) | СОЕДИНЕНИЯ ТЕТРАГИДРОЦИКЛОПЕНТА[b]ИНДОЛА В КАЧЕСТВЕ МОДУЛЯТОРОВ РЕЦЕПТОРА АНДРОГЕНОВ | |
HK1113790A1 (en) | Selurampanel | |
NO20071299L (no) | Vedvarende frigivelse farmasoytisk sammensetning av tolterodine | |
BR112014011981A2 (pt) | formulações farmacêuticas | |
ATE541573T1 (de) | Pharmazeutische zusammensetzung enthaltend lapatinib | |
EA201001747A1 (ru) | Бензоксазиноновые производные, действующие в качестве агониста бета-2-адренорецептора, для лечения респираторных расстройств | |
EA200801614A1 (ru) | Фармацевтическая композиция, содержащая монтелукаст | |
MY150988A (en) | Novel derivatives of ( bridged piperazinyl)-1-alkanone and use thereof as p75 inhibitors | |
WO2007076091A3 (en) | Treatment of viral infections using a tissue factor inhibitor | |
ATE460934T1 (de) | Pharmazeutische zubereitungen von ciprofloxacin | |
ATE496899T1 (de) | Tetrahydro- und dihydrochinazolinone | |
GB2418855B (en) | Use of ethyl lactate as an excipient for pharmaceutical compositions | |
UA92469C2 (en) | Fumarate of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl amino benzonitrile | |
CR9032A (es) | Fumarato de 4-((4-((4-(2-cianoetenil)-2,6-dimetilfenil)amino-2- pirimidinil)amino)benzonitrilo | |
BRPI1006611A2 (pt) | "n' -(metilsulfonil)-1 - [tiofen-2-il]-1, 4-dihidropiridina -3- carbohidrazida, composto de fórmula (i), composição farmacêutica, método de tratamento de uma neuropatia e uso de um composto" | |
EA200901205A1 (ru) | Фармацевтическая композиция, содержащая соль розиглитазона |